State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes DOI Creative Commons
Elisa Tassinari,

Linda Danielli,

Andrea Marchetti

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 21(1)

Published: Dec. 19, 2024

In recent years, several clinical trials focused on the potential role of immune-checkpoint inhibitors (ICIs) in adjuvant treatment muscle-invasive urothelial cancer (UC). Heretofore, only anti-programmed death protein 1 (anti-PD1) nivolumab received European Medical Agency (EMA) approval for cisplatin-unfit patients. our work, we deeply analyzed results three pivotal studies view rapidly evolving therapeutic advanced UC's scenario. Furthermore, there are ongoing research to investigate ICIs and other emerging immune agents this setting; awaited. Additionally, current efforts have been made assess these earlier disease settings, particularly high-risk non-muscle-invasive bladder (NMIBC). review, predictive and/or prognostic biomarkers that may improve patient selection efficacy. To conclude, highlighted upcoming changes could redefine standard care patients with early-stage UC.

Language: Английский

Efficiency of transurethral en‐bloc resection vs. conventional transurethral resection for non‐muscle‐invasive bladder cancer: An umbrella review DOI Creative Commons
Dengxiong Li, Qingxin Yu,

Ruicheng Wu

et al.

Cancer Medicine, Journal Year: 2024, Volume and Issue: 13(11)

Published: May 31, 2024

Abstract Background En‐Bloc transurethral resection of bladder tumor (ERBT) was clinically used to resect non‐muscle‐invasive cancer (NMIBC). However, discrepancies persist regarding the comparisons between ERBT and conventional (cTURBT). Methods We conducted a comprehensive search in PubMed, Embase, Web Science, Cochrane Database Systematic Reviews, performed manual searches reference lists collect extract data. Data evaluation carried out using Review Manager 5.4.0, Rx64 4.1.3, relevant packages. Results There were nine eligible meta‐analyses RCTs our study. NMIBC patients undergoing significant associated with lower rate perforation obturator nerve reflex compared those receiving cTURBT. Our pooled result indicated that cTURBT required similar operation time. Regarding postoperative outcomes, demonstrated superior performance terms detrusor muscle presence, catheterization time, residual tumor. exhibited higher three‐month recurrence‐free survival (RFS) ( p < 0.05; I 2 = 0%). In bipolar subgroup, had better 12‐month RFS than Simultaneously, exclusion Hybrid Knife data revealed improvement 50%). Conclusion Using combination umbrella review meta‐analysis, we or comparable perioperative outcome improved 3 12 month suggest maybe surgical method for

Language: Английский

Citations

11
Chemotherapy-enhanced endoscopic submucosal En Bloc dissection vs. conventional TURBT for NMIBC: a comparative study DOI
Xi Liu,

Yiding Wang,

Zhe Wang

et al.

International Urology and Nephrology, Journal Year: 2025, Volume and Issue: unknown

Published: March 9, 2025

Language: Английский

Citations

0
Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature DOI Creative Commons

Rei Ben Muvhar,

Reem Paluch,

Matan Mekayten

et al.

Research and Reports in Urology, Journal Year: 2025, Volume and Issue: Volume 17, P. 69 - 85

Published: March 1, 2025

Bladder cancer management, particularly non-muscle-invasive bladder (NMIBC), has evolved significantly due to advancements in imaging techniques and surgical methodologies. Enhanced tumor visualization methods, including Photodynamic Diagnosis (PDD) Narrow-Band Imaging (NBI), offer improved detection rates for both papillary tumors carcinoma situ (CIS), compared traditional white-light cystoscopy (WLC). Recent studies suggest that these technologies enhance diagnostic accuracy, reduce recurrence rates, improve oncological outcomes. Additionally, transurethral resection of (TURBT), performed with advanced imaging, demonstrated better quality, terms detrusor muscle presence. Despite innovations, challenges remain the long-term impact on recurrence-free progression-free survival. Artificial intelligence (AI) integration into cystoscopic further promises enhanced precision cost-effective management. As personalized treatment paradigms emerge, predictive biomarkers, genomic pathological markers, may help stratify patients aggressive treatment, sparing those at lower risk from unnecessary interventions. Future research should focus validating AI models combining them modalities refine protocols further. These collectively represent a significant leap toward medicine care.

Language: Английский

Citations

0
Side effects of prostate cancer therapies and potential management DOI Open Access
Jinfeng Xiao, Meihui Zhang,

Donghai Wu

et al.

Journal of Biological Methods, Journal Year: 2024, Volume and Issue: 11(3), P. e99010018 - e99010018

Published: Aug. 22, 2024

Prostate cancer (PCa) remains a significant health challenge, necessitating diverse therapeutic interventions to manage the disease effectively. While these treatments offer promising outcomes, they are often accompanied by range of side effects that can impact patient quality life and treatment compliance. This review provides an overview common associated with various PCa therapies, including prostatectomy, radiation therapy, thermal hormone chemotherapy, targeted drug among others. We summarized discussed reported encompassing ureteral problems, sexual issues, gastrointestinal symptoms, fatigue, anemia, thrombocytopenia, hematologic abnormalities, nausea, vomiting, liver enzyme elevation. Specific managements, such as personalized plans, proactive symptom monitoring, supportive care interventions, hematological assessments, crucial in mitigating optimizing outcomes. By prioritizing patient-centered tailored health-care providers enhance efficacy improve overall well-being individuals undergoing therapies.

Language: Английский

Citations

1
GREM1 may be a biological indicator and potential target of bladder cancer DOI Creative Commons
Qingxin Yu, Shanshan Xu,

Shouxiang Weng

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: Oct. 7, 2024

Gremlin 1 (GREM1) can regulate the development of many cancers. However, a few studies have revealed role GREM1 in bladder cancer (BC). To evaluate expression and potential function cancer, we used R version 3.6.3 related packages to analyze data from common databases. Samples our institution were assessed by immunohistochemical staining (IHC), which was approved Institutional Ethics Committee (K20220830). highly expressed BC tissues according TCGA IHC data. Data TCGA, GSE31684, GSE32894, showed that has significant prognostic value for patients. is involved immune metabolism-related pathways. According TIDE algorithm, 61.0% patients with low responded well immunotherapy, compared only 13.3% high group. High associated sensitivity cisplatin, docetaxel, gemcitabine, vinblastine. Thus, predict prognosis responses immunotherapy chemotherapy patients, making it biomarker therapeutic target.

Language: Английский

Citations

1
Role of repeat transurethral resection in no-muscle-invasive bladder tumour: an umbrella review DOI Creative Commons
Qingxin Yu,

Ruicheng Wu,

Zhouting Tuo

et al.

Therapeutic Advances in Medical Oncology, Journal Year: 2024, Volume and Issue: 16

Published: Jan. 1, 2024

Background: Repeat transurethral resection of bladder tumour (reTURB) is a conventional treatment for non-muscle-invasive cancer (NMIBC) to enhance prognosis. However, the necessity reTURB in NMIBC remains controversial owing upstaging treatments and new evidence. Objectives: We performed an umbrella review determine need patients with NMIBC. Design: extracted data from meta-analyses that were screened out after systematic search PubMed, Embase, Web Science Cochrane Database Systematic Reviews. Methods: Risk Bias Reviews Grading Recommendations, Assessment, Development Evaluation tools used assess quality each included meta-analysis outcomes. Results: Our study seven meta-analyses. Two studies assessed efficiency who underwent en bloc tumours (ERBT). Patients ERBT reported low residual rates 5.9% 0.3%, respectively. Conversely, (cTURB) had high rates. cTURB significantly improved 1-year recurrence-free survival (RFS) compared those initial alone. In terms progression-free (PFS), PFS subgroup analyses ERBT, did not affect RFS received ERBT. Currently, only limited number randomised clinical trials have evaluated reTURB, various factors influenced its efficacy. Conclusion: There was significant variation outcomes among undergoing reTURB. The efficacy depend on numerous factors, such as surgical approach, equipment medication usage. eligible may constitute group does require Further are required validate these findings. Registration: This registered International Prospective Register (CRD42023439078).

Language: Английский

Citations

1
Current opinions regarding the clinical utility of en bloc resection in the treatment of non-muscle invasive bladder cancer—a review of the literature DOI Creative Commons
Wenbo Gao

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Oct. 19, 2024

Language: Английский

Citations

1
Association between time to treatment and bladder cancer survival: a population-based analysis DOI Open Access
Xiaojie Hou, Nan Li,

Lin Ruan

et al.

Translational Andrology and Urology, Journal Year: 2024, Volume and Issue: 13(9), P. 2079 - 2091

Published: Sept. 1, 2024

Cancer treatment delay is a global health system issue. However, data concerning the impact of delays on survival in bladder cancer remain controversial. This study sought to evaluate time from diagnosis outcomes patients US Surveillance, Epidemiology, and End Results (SEER) database.

Language: Английский

Citations

0
Research Hotspots and Trends in Global Cancer immunometabolism:A Bibliometric Analysis from 2000 to 2023 DOI Creative Commons
Shupeng Chen, Jie Liu,

G Q He

et al.

Journal of Multidisciplinary Healthcare, Journal Year: 2024, Volume and Issue: Volume 17, P. 5117 - 5137

Published: Nov. 1, 2024

Cancer poses a major global health challenge, and immunotherapy, known as the third revolution in cancer treatment, has brought new hope to patients. The emerging field of immunometabolism further enhanced safety efficacy immunotherapy. Over past two decades, this rapidly evolved oncology, leading numerous significant findings. This review systematically examines literature on cancer, visualizing research trends identifying future directions.

Language: Английский

Citations

0
The evolving role of multidisciplinary teams in optimizing Non-Muscle Invasive bladder cancer Care DOI
Amanda A. Myers,

Alexis R. Steinmetz,

Ashish M. Kamat

et al.

Expert Review of Anticancer Therapy, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 6

Published: Oct. 16, 2024

Introduction Non-muscle invasive bladder cancer (NMIBC) represents a significant portion of cases and imposes substantial economic burden, stemming from both direct treatment costs long-term surveillance. As the landscape evolves with advances in immunotherapy targeted therapies, multidisciplinary approach to management is increasingly crucial for optimizing patient outcomes resource utilization.

Language: Английский

Citations

0